Bioanalytical and CMC Services for small molecules, biologics and
advanced therapies for the life science industry
The Kymos Group is an analytical CRO with three European laboratories devoted to providing bioanalytical and CMC services for the life science industry throughout the entire product life cycle: from early research and development to manufacturing and commercialization. We are GLP- and GMP-certified, have been successfully inspected by the EMA and the FDA and are experts in analytical and quality control work with small molecules, biologics and oligonucleotides. Kymos provides services to clients worldwide in the pharmaceutical, biotechnology, veterinary, fine chemistry, cosmetic and nutraceutical industries.
Testimonials
“We are currently developing multiple new biosimilar projects and consider Kymos one of the best CROs in Europe for drug release and testing.”
“We were positively impressed when Kymos reacted to our needs by investing in their stability capabilities, and now, two years down the line, with projects in full-swing, I can safely say that we made the right choice. In Kymos we have found a reliable, committed, trustworthy and professional partner.”
“Back in 2017 there weren’t many analytical CROs able to carry out Franz cell assays and Kymos’ pioneering work was pivotal for the registration of our product.”
“Kymos offered superior historical expertise by being exposed to so many different clients, pharmacological compounds, and therapeutic areas. They addressed and anticipated very diverse problems.”
“I have had a long and fruitful experience with Kymos and have a huge interest in their participation owing to their reliability.”
“Prolytic is our analytical partner throughout the entire drug development process. Such a long and complex process requires a laboratory you can trust. Professional yet flexible, Prolytic accompanies us through the preclinical and clinical phases.”
“Establishing robust miRNA methods for valuable results is tricky. The team at Prolytic have been a key collaboration partner. With their 30 years of experience in bioanalytics and broad know-how in different techniques, study types, and substance groups, we were able to quickly develop a reproducible and reliable analysis method for miRNAs.”
Latest News
New FDA Guideline for Oligonucleotide Therapeutics
In June 2024, the FDA published the final version of the guideline titled “Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics Guidance for Industry”. This document replaces the draft from 2022 and provides (...) Read more
New EMA Guideline on Topical Products: Impact on IVRT and IVPT
The European Medicines Agency (EMA) announced in October 2024 the adoption of the long-awaited guideline on the Quality and Equivalence of Topical Products. The final document was drafted back in 2018 and will be coming (...) Read more
DG-GT Meeting: Dresden, DE | 10-11 Mar 2025
BIO CHINA 2025: Suzhou, CHN | 13-15 Mar 2025
BIO-Europe Spring: Milan, IT | 25-26 Mar 2025
German Pharm-Tox Summit: Hannover, DE | 25-28 Mar 2025
German Biotech Days: Heidelberg, DE | 09-10 Apr 2025
MEET2WIN: Bourdeaux, FR | 06-07 May 2025
BIO KOREA 2025: Seoul, KR | 07-09 May 2025
BIONNALE 2025: Berlin, DE | 14-15 May 2025
Innovation for Cell and Gene Therapies (ICGT): Paris, FR | 22 May 2025
MabDesign Partnering Day: Lyon, FR | 02 Jun 2025
Congrès Polepharma Biotesting: Evreux, FR | 04-05 Jun 2025
International Oligonucleotides and Peptides Conference: Prague, CZ | 09-11 Jun 2025
AFI Simposio: Rimini, IT | 11-13 Jun 2025
Antibody Industrial Symposium (AIS): Tours, FR | 25-26 Jun 2025
CPHI 2025: Frankfurt, DE | 28-30 Oct 2025
